Rachel Bowman
Family Medicine · Knoxville, TNNPI 1386864338
Payments from drug & device makers
Across 567 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$690
- Pfizer$440
- Takeda Pharmaceuticals U.S.A., Inc.$353
- plus $4K from 40 others
What the payments were for
- Food & beverage$8,643100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$250
- Kerendia$122
How this compares
$8,655 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $56,017 |
| EliquisApixaban | 53 | $52,519 |
| MounjaroTirzepatide | 17 | $24,948 |
| TrulicityDulaglutide | 15 | $20,909 |
| JardianceEmpagliflozin | 18 | $19,126 |
| LinzessLinaclotide | 15 | $13,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,284 |
| XareltoRivaroxaban | 16 | $11,262 |
| EntrestoSacubitril/Valsartan | 11 | $11,225 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $11,099 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,237 |
| MyrbetriqMirabegron | 13 | $6,124 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,966 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,995 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,078 | $56,01749 claims |
| PfizerEliquis | $440 | $52,51953 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,142 | $45,85732 claims |
| Boehringer IngelheimJardiance | $175 | $19,12618 claims |
| AbbVieLinzess | $1,387 | $13,80815 claims |
| GSKTrelegy Ellipta | $117 | $13,28414 claims |
| Johnson & JohnsonXarelto | $18 | $11,26216 claims |
| NovartisEntresto | $314 | $11,22511 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $54 | $11,09914 claims |
| AstraZenecaBreztri Aerosphere | $261 | $9,23715 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $6,12413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $1,411175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Knoxville
- Rickey ManningKnoxville$8.1M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Emily HubbsKingsport$2.8M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.